title: [Escherichia coli meningitis during bacteremia in the Ibrahima-Diop-Mar infectious diseases clinic, Dakar Fann National Hospital Center (Senegal)].
abstract: OBJECTIVE
  The aim of this study was to describe epidemiological, clinical, and bacteriological aspects of Escherichia coli bacteremia and meningitis in the Ibrahima-Diop-Mar infectious diseases clinic, Dakar Fann National Hospital Center (Senegal).
  
  
  METHODS
  Data was collected from the bacteriology laboratory and hospitalization files.
  
  
  RESULTS
  57 cases of E. coli bacteremia were reported. Among them, 10 were associated with meningitis. AIDS was diagnosed in 74% of the cases. The global lethality rate was 47% but this rate was higher in cases of associated meningitis (80 vs 37%) and in AIDS patients (50 vs 27%). Ceftriaxone, aztreonam, gentamicin, and ciprofloxacin were active on more than 95% of strains but cotrimoxazole was active on only 49% of the strains. Resistance to cotrimoxazole was higher among E. coli strains isolated from AIDS patients (62 vs 13%).
  
  
  CONCLUSIONS
  The low susceptibility to cotrimoxazole might increase the incidence of E. coli infections among patients with AIDS. It is therefore important to find an alternative to cotrimoxazole chemoprophylaxis.
authors.affiliation: Clinique des maladies infectieuses Ibrahima-Diop-Mar du Centre hospitalier national de Fann, BP 15499, Dakar Fann, Sénégal. seydi.moussa@caramail.com
authors.forename: M
authors.initials: M
authors.lastname: Seydi
authors.forename: M
authors.initials: M
authors.lastname: Soumaré
authors.forename: A I
authors.initials: AI
authors.lastname: Sow
authors.forename: B M
authors.initials: BM
authors.lastname: Diop
authors.forename: P S
authors.initials: PS
authors.lastname: Sow
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019072:Antibiotic Prophylaxis; D016470:Bacteremia / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D002648:Child; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D004926:Escherichia coli / Q000187:drug effects / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000453:epidemiology*; D005260:Female; D006779:Hospitals, Public / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D016920:Meningitis, Bacterial / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology / Q000382:microbiology; D008875:Middle Aged; D012189:Retrospective Studies; D012675:Senegal / Q000453:epidemiology; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D015662:Trimethoprim, Sulfamethoxazole Drug Combination